Literature DB >> 19077381

A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients.

Tomoko Nozu1, Mitsuko Kondo, Kazuo Suzuki, Jun Tamaoki, Atsushi Nagai.   

Abstract

BACKGROUND: The existence of antineutrophil cytoplasmic antibody (ANCA)-positive pulmonary fibrosis (PF) has recently been recognized.
OBJECTIVES: The aim of this study was to clarify whether there is any difference in the clinical features between ANCA-positive PF and ANCA-negative PF.
METHODS: A retrospective study was carried out on 53 patients with idiopathic PF whose myeloperoxidase (MPO)- and proteinase 3 (PR3)-ANCA levels were measured. After dividing the patients into ANCA-positive and ANCA-negative PF, we compared their symptoms, pulmonary function tests, chest CT findings, bronchoalveolar lavage findings, the effects of therapy and survival rates.
RESULTS: 17 of the 53 patients with idiopathic PF were MPO-ANCA-positive, 2 were PR3-ANCA-positive and 34 were negative for both ANCA types. Lactate dehydrogenase was lower in ANCA-positive PF than in ANCA-negative PF. However, there was no significant difference in the symptoms, lung function tests, CT findings and bronchoalveolar lavage findings. Corticosteroid therapy tended to be more effective in ANCA-positive PF, but the overall survival rate in ANCA-positive PF was not different from that in ANCA-negative PF. However, the low-titer (<50 EU) group showed better survival than the high-titer (> or =50 EU) group in ANCA-positive PF. ANCA titers of the patients who developed microscopic polyangiitis were higher than of those who did not develop it in ANCA-positive PF.
CONCLUSIONS: Our studies showed little difference in the clinical features between ANCA-positive and ANCA-negative PF. However, it may be important to measure ANCA when idiopathic PF is diagnosed, because a high titer of ANCA suggests a poor prognosis and the association with microscopic polyangiitis. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19077381     DOI: 10.1159/000183754

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  20 in total

1.  Radiologic and pathologic characteristics of myeloperoxidase-antineutrophil cytoplasmic antibody-associated interstitial lung disease: a retrospective analysis.

Authors:  Misbah Baqir; Eunhee E Yi; Thomas V Colby; Christian W Cox; Jay H Ryu; Ulrich Specks
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 2.  Interstital lung disease in ANCA vasculitis.

Authors:  Marco A Alba; Luis Felipe Flores-Suárez; Ashley G Henderson; Hong Xiao; Peiqi Hu; Patrick H Nachman; Ronald J Falk; J Charles Jennette
Journal:  Autoimmun Rev       Date:  2017-05-04       Impact factor: 9.754

3.  Microscopic polyangiitis associated with pulmonary fibrosis.

Authors:  Marcelo Fernandez Casares; Alejandra Gonzalez; Mariano Fielli; Flavia Caputo; Yanina Bottinelli; Marcelo Zamboni
Journal:  Clin Rheumatol       Date:  2014-05-27       Impact factor: 2.980

4.  Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Gabrielle Y Liu; Iazsmin Bauer Ventura; Natalia Achtar-Zadeh; Brett M Elicker; Kirk D Jones; Paul J Wolters; Harold R Collard; Ayodeji Adegunsoye; Mary E Strek; Brett Ley
Journal:  Chest       Date:  2019-06-07       Impact factor: 9.410

5.  Pyrexia of unknown origin and pulmonary fibrosis as a presentation of MPO-ANCA associated vasculitis.

Authors:  O Shields; A Shah; B Mann
Journal:  BMJ Case Rep       Date:  2011-04-15

6.  Clinical Implication of Proteinase-3-antineutrophil Cytoplasmic Antibody in Patients with Idiopathic Interstitial Pneumonias.

Authors:  Hironao Hozumi; Noriyuki Enomoto; Yoshiyuki Oyama; Masato Kono; Tomoyuki Fujisawa; Naoki Inui; Yutaro Nakamura; Takafumi Suda
Journal:  Lung       Date:  2016-02-12       Impact factor: 2.584

Review 7.  Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist.

Authors:  Sakae Homma; Aika Suzuki; Keita Sato
Journal:  Clin Exp Nephrol       Date:  2012-11-28       Impact factor: 2.801

Review 8.  Limited pulmonary MPA, a new MPA entity? A rheumatologist's perspective.

Authors:  Luis F Flores-Suárez
Journal:  Clin Exp Nephrol       Date:  2012-11-28       Impact factor: 2.801

Review 9.  Diagnostic workup for diffuse parenchymal lung disease: schematic flowchart, literature review, and pitfalls.

Authors:  Barbara Deconinck; Johny Verschakelen; Johan Coolen; Eric Verbeken; Geert Verleden; Wim Wuyts
Journal:  Lung       Date:  2012-11-13       Impact factor: 3.777

10.  Pulmonary Limited MPO-ANCA Microscopic Polyangiitis and Idiopathic Lung Fibrosis in a Patient with a Diagnosis of IgA Nephropathy.

Authors:  Alwin Tilanus; Patricia Van der Niepen; Caroline Geers; Karl Martin Wissing
Journal:  Case Rep Nephrol       Date:  2015-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.